001     127043
005     20240228140903.0
024 7 _ |a 10.1158/1078-0432.CCR-14-2650
|2 doi
024 7 _ |a pmid:25957288
|2 pmid
024 7 _ |a pmc:PMC4537825
|2 pmc
024 7 _ |a 1078-0432
|2 ISSN
024 7 _ |a 1557-3265
|2 ISSN
024 7 _ |a altmetric:3981194
|2 altmetric
037 _ _ |a DKFZ-2017-03069
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Mack, Stephen C
|b 0
245 _ _ |a Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype.
260 _ _ |a Philadelphia, Pa. [u.a.]
|c 2015
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1508835443_20352
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Myxopapillary ependymoma (MPE) is a distinct histologic variant of ependymoma arising commonly in the spinal cord. Despite an overall favorable prognosis, distant metastases, subarachnoid dissemination, and late recurrences have been reported. Currently, the only effective treatment for MPE is gross-total resection. We characterized the genomic and transcriptional landscape of spinal ependymomas in an effort to delineate the genetic basis of this disease and identify new leads for therapy.Gene expression profiling was performed on 35 spinal ependymomas, and copy number profiling was done on an overlapping cohort of 46 spinal ependymomas. Functional validation experiments were performed on tumor lysates consisting of assays measuring pyruvate kinase M activity (PKM), hexokinase activity (HK), and lactate production.At a gene expression level, we demonstrate that spinal grade II and MPE are molecularly and biologically distinct. These are supported by specific copy number alterations occurring in each histologic variant. Pathway analysis revealed that MPE are characterized by increased cellular metabolism, associated with upregulation of HIF1α. These findings were validated by Western blot analysis demonstrating increased protein expression of HIF1α, HK2, PDK1, and phosphorylation of PDHE1A. Functional assays were performed on MPE lysates, which demonstrated decreased PKM activity, increased HK activity, and elevated lactate production.Our findings suggest that MPE may be driven by a Warburg metabolic phenotype. The key enzymes promoting the Warburg phenotype: HK2, PKM2, and PDK are targetable by small-molecule inhibitors/activators, and should be considered for evaluation in future clinical trials for MPE.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a HIF1A protein, human
|2 NLM Chemicals
650 _ 7 |a Hypoxia-Inducible Factor 1, alpha Subunit
|2 NLM Chemicals
650 _ 7 |a Hexokinase
|0 EC 2.7.1.1
|2 NLM Chemicals
650 _ 7 |a Protein-Serine-Threonine Kinases
|0 EC 2.7.11.1
|2 NLM Chemicals
650 _ 7 |a pyruvate dehydrogenase (acetyl-transferring) kinase
|0 EC 2.7.11.2
|2 NLM Chemicals
700 1 _ |a Agnihotri, Sameer
|b 1
700 1 _ |a Bertrand, Kelsey C
|b 2
700 1 _ |a Wang, Xin
|b 3
700 1 _ |a Shih, David J
|b 4
700 1 _ |a Witt, Hendrik
|0 P:(DE-He78)046fd145f1008f83f6236580727bbc0f
|b 5
|u dkfz
700 1 _ |a Hill, Nadia
|b 6
700 1 _ |a Zayne, Kory
|b 7
700 1 _ |a Barszczyk, Mark
|b 8
700 1 _ |a Ramaswamy, Vijay
|b 9
700 1 _ |a Remke, Marc
|b 10
700 1 _ |a Thompson, Yuan
|b 11
700 1 _ |a Ryzhova, Marina
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Massimi, Luca
|b 13
700 1 _ |a Grajkowska, Wieslawa
|b 14
700 1 _ |a Lach, Boleslaw
|b 15
700 1 _ |a Gupta, Nalin
|b 16
700 1 _ |a Weiss, William A
|b 17
700 1 _ |a Guha, Abhijit
|b 18
700 1 _ |a Hawkins, Cynthia
|b 19
700 1 _ |a Croul, Sidney
|b 20
700 1 _ |a Rutka, James T
|b 21
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 22
|u dkfz
700 1 _ |a Korshunov, Andrey
|0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
|b 23
|u dkfz
700 1 _ |a Pekmezci, Melike
|b 24
700 1 _ |a Tihan, Tarik
|b 25
700 1 _ |a Philips, Joanna J
|b 26
700 1 _ |a Jabado, Nada
|b 27
700 1 _ |a Zadeh, Gelareh
|b 28
700 1 _ |a Taylor, Michael D
|b 29
773 _ _ |a 10.1158/1078-0432.CCR-14-2650
|g Vol. 21, no. 16, p. 3750 - 3758
|0 PERI:(DE-600)2036787-9
|n 16
|p 3750 - 3758
|t Clinical cancer research
|v 21
|y 2015
|x 1557-3265
909 C O |o oai:inrepo02.dkfz.de:127043
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)046fd145f1008f83f6236580727bbc0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 23
|6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CLIN CANCER RES : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CLIN CANCER RES : 2015
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)G380-20160331
|k G380
|l KKE Neuropathologie
|x 1
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)G380-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21